Management of cutaneous toxicities induced by epidermal growth factor receptor inhibitors: A review;Prise en charge des toxicités cutanées des thérapies dirigées contre les récepteurs du facteur de croissance épidermique: Revue de la littérature

Revue Medicale de Bruxelles

Volumn 29, Issue 6, 2008, Pages 552-558

  Mestdagh, K ^a,b,e   Fink, W ^a,b,c   Hendlisz, A ^d   Heenen, M ^a   Vereecken, P ^a,b,d  

^a ERASME HOSPITAL   (Belgium)

^b HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^c Klinische Kooperationseinheit Dermato Onkologie (dkfz)

^d JULES BORDET INSTITUTE   (Belgium)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acneiform eruption; EGFR inhibitors; Epidermal growth factor receptor; Rash

Indexed keywords

ACICLOVIR; ALCOHOL; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; COMFEEL; DOXYCYCLINE; DUODERM; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERYTHROMYCIN; FUSIDATE SODIUM; METRONIDAZOLE; MINOCYCLINE; PROPYLENE GLYCOL; SALICYLIC ACID; STAPHYCID; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DISEASE SEVERITY; HERPES SIMPLEX; HUMAN; PATHOPHYSIOLOGY; PRURITUS; RASH; REVIEW; SKIN ALLERGY; SKIN EXFOLIATION; SKIN TOXICITY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN;

EID: 58149353011     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Marshall J : Clinical Implications of the Mechanism of Epidermal Growth Factor Receptor Inhibitors. Cancer 2006 ; 107 : 1207-18
2. Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M : Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005 ; 4 : 650-8
3. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ : Phase II trial of cetuximab in patients with refractory colorectal cancer that expresss the epidermal growth factor receptor. J Clin Oncol 2004 ; 22 : 1201-8
4. Agero AL, Dusza SW, Benvenuto-Andrade C et al. : Dermatologic side effects associated with epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006 ; 55 : 657-70
5. Kurai J, Chikumi H, Hashimoto K et al. : Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines. Clin Cancer Res 2007 ; 13 : 1552-61
6. Segaert S, Van Cutsem E : Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005 ; 16 : 1425-33
7. Segaert S : Stratégies de prise en charge des effets secondaires liés à l'Erbitux®. Firme Merck
8. Cunningham D, Humblet Y, Van Cutsem E et al. : Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 ; 351 : 337-45
9. Perez-Soler R : Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancers. Clin Lung Cancer 2006 : 8 (Suppl 1) : S7-14
10. Perez-Soler R, Delord JP, Halpern A et al. : HER1/EGFR inhibitor-associated rash : future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005 ; 10 : 345-56
11. Shah NT, Kris MG, Pao W et al. : Practical Management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005 ; 23 : 165-74
12. Lacouture ME, Lai SE : The PRIDE (Papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryeness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006 ; 155 : 852-4
13. Lacouture ME, Boerner SA, LoRusso PM : Non-rash skin toxicities associated with novel targeted therapies. Clin Lung Cancer 2006 ; 8 (Suppl 1) : S36-42
14. Peréz-Soler R, Saltz L : Cutaneous adverse effects with HER1/EGFR-targeted agents : Is there a silver lining ? J Clin Oncol 2005 ; 23 : 5235-46
15. Amador ML, Oppenheimer D, Perea S et al. : An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004 ; 64 : 9139-43
16. Baselga J : Skin as a surrogate tissue for pharmacodynamic end points : is it deep enough ? Clin Cancer Res 2003 ; 9 : 2389-90
17. Van Cutsem E : Cetuximab dose escalation can benefit some metastatic colorectal patients. 31st Congress of the European Society for Medical Oncology (ESMO), Istanbul, 2006
18. Tepjar S, Peeters M, Humblet Y et al. : Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST) : Pharmacokinetic (PK), Pharmacodynamique (PD) and efficacy data. J Clin Oncol 2007 ; 25 : 18S (Suppl) : 4037
19. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P : Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2003 ; 6 : 491-500